Skip to main content

Table 5 One-way sensitivity analysis (per patient level)

From: Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany

Parameter Variation Cost / QALY Incremental cost per QALY gained (€), Bedaquiline
BR alone Linezolid plus BR Delamanid plus BR Bedaquiline plus BR Versus BR alone Versus Linezolid plus BR Versus Delamanid plus BR
Base case 60,962 / 3.68 80,460 / 3.91 81,079 / 4.21 85,575 / 4.79 22,238 5787 7774
BR SCC rates at 6-months +20% (37.2% SCC to 44.6%) 58,648 / 4.00 78,179 / 4.24 78,192 / 4.58 82,170 / 5.17 20,105 4316 6713
−20%(37.2% SCC to 29.7%) 63,037 / 3.36 82,518 / 3.56 83,807 / 3.82 89,010 / 4.35 26,384 8196 9802
Effect of bedaquiline on SCC rates +20% 60,962 / 3.68 80,460 / 3.91 81,079 / 4.21 84,384 / 5.01 17,711 3569 4162
−20% 60,962 / 3.68 80,460 / 3.91 81,079 / 4.21 86,986 / 4.52 30,960 10,565 18,921
Maximum duration of linezolid treatment 42 to 24 weeks (duration of Bedaquiline treatment) 60,962 / 3.68 73,307 / 3.88 81,079 / 4.21 85,575 / 4.79 22,238 13,553 7774
Relapse after cure +20% 61,232 / 3.65 80,732 / 3.87 81,421 / 4.16 85,716 / 4.77 21,809 5508 7092
−20% 60,684 / 3.72 80,180 / 3.95 80,729 / 4.26 85,433 / 4.81 22,701 6094 8552
Utility weight for no cure plus20% 60,962 / 3.95 80,460 / 4.16 81,079 / 4.46 85,575 / 5.02 22,988 5983 8056
−20% 60,962 / 3.48 80,460 / 3.72 81,079 / 4.04 85,575 / 4.66 20,973 5465 7337
Utility for cure Perfect health after cure 60,962 / 4.26 80,460 / 4.53 81,079 / 4.89 85,575 / 5.57 18,770 4905 6596
Discount rate 0% cost 3% outcomes 62,032 / 3.68 81,524 / 3.91 82,098 / 4.21 86,538 / 4.79 22,141 5672 7676
6% costs 3% outcomes 60,039 / 3.68 79,547 / 3.91 80,210 / 4.21 84,765 / 4.79 22,340 5903 7875
3% costs 0% outcomes 60,962 / 4.12 80,460 / 4.38 81,079 / 4.73 85,575 / 5.4 19,224 5015 6712
3% costs 6% outcomes 60,962 / 3.33 80,460 / 3.52 81,079 / 3.79 85,575 / 4.29 25,473 6611 8914
Cost for BR medication +20% 66,824 / 3.68 86,271 / 3.91 86,831 / 4.21 91,177 / 4.79 22,003 5550 7514
−20% 55,099 / 3.68 74,649 / 3.91 75,327 / 4.21 79,974 / 4.79 22,474 6024 8034
Cost for AE’s +20% 60,962 / 3.68 80,484 / 3.91 81,079 / 4.21 85,579 / 4.79 22,242 5764 7779
−20% 60,962 / 3.68 80,436 / 3.91 81,078 / 4.21 85,572 / 4.79 22,235 5811 7768
  1. AE Adverse event, BR Background regimen, QALY Quality-adjusted life-year, SCC Sputum culture conversion